<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093820</url>
  </required_header>
  <id_info>
    <org_study_id>2010 DR 2029</org_study_id>
    <nct_id>NCT01093820</nct_id>
  </id_info>
  <brief_title>Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction</brief_title>
  <acronym>BEATSTEMIPi</acronym>
  <official_title>Documentation of Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (BEAT-STEMI Pilot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      Based on available pharmacokinetic data from healthy volunteers we hypothesize that the
      administration of a cumulative dose of 210μg of the continuous erythropoietin receptor
      activator, Mircera® (Roche), during 3 months post percutaneous coronary intervention (PCI)
      does not result in hemoglobin (Hb) levels &gt;15 g/dl in patients with ST-segment elevation
      myocardial infarction (STEMI)

      Design:

      Prospective, open label single center pilot study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot trial will include 8 patients. The inclusion of 8 patients will allow to perform
      representative statistics of expected Hb kinetics in response to Mircera®.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients exceeding Hemoglobin (Hb) of 15 g/L within 3 months</measure>
    <time_frame>three months</time_frame>
    <description>measurement of Hb at baseline and month 1, 2 and 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal change in Hb within 3 months relative to baseline</measure>
    <time_frame>three months</time_frame>
    <description>measurement of Hb at baseline and month 1, 2 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in Hb from baseline to 1 months</measure>
    <time_frame>first month</time_frame>
    <description>measurement of Hb at baseline and month 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal change in Hematocrit (Hk) within 3 months relative to baseline</measure>
    <time_frame>three months</time_frame>
    <description>measurement of Hk at baseline and month 1, 2 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in platelet count within 3 months relative to baseline</measure>
    <time_frame>three months</time_frame>
    <description>measurement of platelet count at baseline and month 1, 2 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety endpoints including all cause mortality,myocardial infarction,stroke,hospitalization,life threatening arrhythmias,thromboembolic events,stent thrombosis,poorly controlled hypertension despite therapy,seizures</measure>
    <time_frame>three months</time_frame>
    <description>follow-up at month 1, 2 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in Hb from 1 to 2 months</measure>
    <time_frame>second month</time_frame>
    <description>measurement of Hb at month 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in Hb from 2 to 3 months</measure>
    <time_frame>third month</time_frame>
    <description>measurement of Hb at month 2 and 3</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Epopoetinum beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methoxy-polyethyleneglycol epoetin beta</intervention_name>
    <description>Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI</description>
    <arm_group_label>Epopoetinum beta</arm_group_label>
    <other_name>Mircera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (age 18 - 80 years) with acute STEMI undergoing PCI

        Main Exclusion Criteria:

          -  Hemoglobin levels &gt;15g/dL

          -  history of a myeloproliferative syndrome

          -  thrombolysis for index infarction

          -  anticipated additional revascularization within 3 months

          -  cardiogenic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Pfisterer, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>February 28, 2012</last_update_submitted>
  <last_update_submitted_qc>February 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myocardial infarction</keyword>
  <keyword>continuous erythropoetin receptor activator</keyword>
  <keyword>Mircera</keyword>
  <keyword>hemoglobin kinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

